Expertise in
16
conditions

Dr. Keisuke Shirai

Hematology Oncology | Palliative Medicine | Oncology
Dartmouth-Hitchcock Health
Dartmouth-Hitchcock Clinic
1 Medical Ctr Dr, 
Lebanon, NH 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
16
conditions
Dartmouth-Hitchcock Health
Dartmouth-Hitchcock Clinic
1 Medical Ctr Dr, 
Lebanon, NH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Keisuke Shirai is a Hematologist Oncology specialist and a Palliative Medicine provider in Lebanon, New Hampshire. Dr. Shirai is highly rated in 16 conditions, according to our data. His top areas of expertise are Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC).

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Palliative Medicine
Oncology
Licenses
Hospice and Palliative Medicine in NH
Hospital Affiliations
Mary Hitchcock Memorial Hospital
Cheshire Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO

Locations

DARTMOUTH-HITCHCOCK CLINIC
1 Medical Ctr Dr, Lebanon, NH 03756

Additional Areas of Focus

Dr. Shirai has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Biological, Procedure, Other
Study Drugs: Nivolumab, Talimogene Laherparevec
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: May 30, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: PV-10, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Enrollment Status: Terminated
Publish Date: August 08, 2023
Intervention Type: Biological
Study Drug: GRN-1201+Pembrolizumab
Study Phase: Phase 2
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Enrollment Status: Terminated
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

68 Total Publications

Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy.
Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy.
Journal: Journal for immunotherapy of cancer
Published: October 15, 2024
Similar Doctors
Expertise in
38
conditions
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology
Expertise in
38
conditions
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
 (0.1 mi)
603-650-5000
Languages Spoken:
English
See accepted insurances

Frederick Lansigan is a Hematologist Oncology specialist and a Hematologist in Lebanon, New Hampshire. Dr. Lansigan is highly rated in 38 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), T-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Konstantin H. Dragnev
Hematology Oncology | Oncology
Expertise in
13
conditions
Dr. Konstantin H. Dragnev
Hematology Oncology | Oncology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
 (0.1 mi)
603-650-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Konstantin Dragnev is a Hematologist Oncology specialist and an Oncologist in Lebanon, New Hampshire. Dr. Dragnev is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Expertise in
14
conditions
Dr. Kathryn C. Hourdequin
Hematology Oncology | Oncology | Hematology
Expertise in
14
conditions
Dr. Kathryn C. Hourdequin
Hematology Oncology | Oncology | Hematology

Mary Hitchcock Memorial Hospital

1 Medical Ctr Dr, 
Lebanon, NH 
 (0.1 mi)
603-650-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kathryn Hourdequin is a Hematologist Oncology specialist and an Oncologist in Lebanon, New Hampshire. Dr. Hourdequin is highly rated in 14 conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shirai's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile